WuXi Signed a License Agreement with GSK to Develop Multiple Novel Bi- & Multi-specific T Cell Engagers to Treat Cancer
Shots:
- Under the terms of the agreement, WuXi will receive $40M up front & is eligible for up to $1.46B in research, development, regulatory & commercial milestones along with undisclosed tiered royalties
- GSK received the worldwide rights to research, develop, manufacture & commercialize a preclinical bispecific Ab that targets TAA on tumor cells & CD3 expression on T cells for the treatment of cancer. GSK also has an option for 3 additional discovery staged bi-/multi-specific TCE Ab
- The agreement validates WuXi’s CD3 platform & WuXiBody platform which assembles mAb sequence pairs into bispecific constructs whereas GSK aims to enhance its oncology portfolio of tumor cell targeting agents
Ref: PRNewswire | Image: WuXi Biologics
Related News:- WuXi Biologics to Acquire Pfizer's Biologics Manufacturing Facilities in China
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
